Caladrius Bioscience News Today

Equities research analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.12). Caladrius Biosciences also reported earnings per share of ($0.10) […]

Dublin, May 30, 2022 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Global Market Report 2022: By Product, By Application, By End-User" report has been...

CARLSBAD, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX) a Fintech company powering commerce experiences,...

Wall Street analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report earnings of ($0.12) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Caladrius Biosciences’ earnings, with estimates ranging from ($0.12) to ($0.11). Caladrius Biosciences reported earnings per share of ($0.19) in the same quarter last […]

Analysts expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) will announce ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.13). Caladrius Biosciences posted earnings per share of ($0.28) […]

Share this article Share this article ResearchAndMarkets.coms offering. Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell & gene therapy market. Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science. T...